Ausun Pharm(SH:603229) Zheng Quan Zhi Xing·2025-07-09 16:25Core Viewpoint - The legal opinion letter from Beijing Hairun Tianwei Law Firm confirms that Zhejiang Aoxiang Pharmaceutical Co., Ltd.'s differentiated equity distribution complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [5]. Group 1: Reasons for Differentiated Equity Distribution - On January 24, 2025, the company’s board approved a plan to repurchase shares using its own and/or raised funds through centralized bidding, intending to use the repurchased shares for equity incentives and/or employee stock ownership plans [2][3]. - The total amount for the repurchase is set between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 14 per share, and the repurchase period is 12 months from the board's approval date [3]. Group 2: Specifics of the Differentiated Equity Distribution Plan - The profit distribution plan involves a cash dividend of RMB 0.10 per share (including tax), totaling RMB 82,829,774.50 (including tax), based on a total share capital of 830,297,145 shares, excluding the repurchased shares [3]. - The total number of shares eligible for distribution is 828,297,745, and there will be no capital reserve conversion to share capital or bonus shares issued this year [3]. Group 3: Calculation Basis for the Differentiated Equity Distribution - The calculation for the ex-rights and ex-dividend reference price is based on the last closing price of RMB 8.74 per share, adjusted for the cash dividend [3]. - The impact on the ex-rights and ex-dividend reference price is calculated to be less than 1%, indicating a minimal effect on the stock price [4].